MedTrace Logo

Effect of Hepatitis C Clearance on Insulin Resistance

NCT04457050 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2020-07-07

No results posted yet for this study

Summary

Chronic hepatitis C infection has been linked to insulin resistance, which is the essential component of metabolic syndrome and type 2 diabetes mellitus. Resistin; an adipokine, has been demonstrated to stimulate the secretion of several inflammatory factors known to play a role in the induction of insulin resistance. we investigated the changes in insulin resistance after hepatitis C clearance in the era of direct antivirals.

Conditions

Interventions

DRUG

Sofosbuvir 400 milligram

single daily dose of 400 milligrams

DRUG

Daclatasvir 60 milligram

single daily dose of 60 milligrams for 12 weeks

DRUG

Ribavirin 400 milligram

weight based dose, 1200 mg for weight \> 75 kilogram, and 1000 milligram if weight \< 75 kilograms for 12 weeks

DRUG

Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab

single daily dose for 12 weeks

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2019-11-01
Completion
2019-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04457050 on ClinicalTrials.gov